Genetic and Epigenetic Changes in Primary Metastatic and Nonmetastatic Colorectal Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Sep 14

PMID 16969349

Citations 30

Authors

E Miranda

A Destro

A Malesci

E Balladore

P Bianchi

E Baryshnikova

G Franchi

E Morenghi

L Laghi

L Gennari

M Roncalli

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer (CRC) develops as multistep process, which involves genetic and epigenetic alterations. K-Ras, p53 and B-Raf mutations and RASSF1A, E-Cadherin and p16INK4A promoter methylation were investigated in 202 CRCs with and without lymph node and/or liver metastasis, to assess whether gene abnormalities are related to a metastogenic phenotype. K-Ras, B-Raf and p53 mutations were detected in 27, 3 and 32% of the cases, with K-Ras mutations significantly associated with metastatic tumour (P=0.019). RASSF1A, E-Cadherin and p16INK4A methylation was documented in 20, 44 and 33% of the cases with p16INK4A significantly associated with metastatic tumours (P=0.001). Overall, out of 202 tumours, 34 (17%) did not show any molecular change, 125 (62%) had one or two and 43 (21%) three or more. Primary but yet metastatic CRCs were prevalent in the latter group (P=0.023) where the most frequent combination was one genetic (K-Ras in particular) and two epigenetic alterations. In conclusion, this analysis provided to detect some molecular differences between primary metastatic and nonmetastatic CRCs, with K-Ras and p16INK4A statistically altered in metastatic tumours; particular gene combinations, such as coincidental K-Ras mutation with two methylated genes are associated to a metastogenic phenotype.

Citing Articles

Genomic Effect of DNA Methylation on Gene Expression in Colorectal Cancer.

Hong J, Rhee J Biology (Basel). 2022; 11(10).

PMID: 36290295 PMC: 9598958. DOI: 10.3390/biology11101388.

Molecular features and gene expression signature of metastatic colorectal cancer (Review).

Poturnajova M, Furielova T, Balintova S, Schmidtova S, Kucerova L, Matuskova M Oncol Rep. 2021; 45(4).

PMID: 33649827 PMC: 7876998. DOI: 10.3892/or.2021.7961.

The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden.

Hallam S, Stockton J, Bryer C, Whalley C, Pestinger V, Youssef H Sci Rep. 2020; 10(1):18900.

PMID: 33144643 PMC: 7641117. DOI: 10.1038/s41598-020-75844-6.

Landscape of Genome-Wide DNA Methylation of Colorectal Cancer Metastasis.

Ili C, Buchegger K, Demond H, Castillo-Fernandez J, Kelsey G, Zanella L Cancers (Basel). 2020; 12(9).

PMID: 32971738 PMC: 7564781. DOI: 10.3390/cancers12092710.

Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.

Liu X, Yang H, Wu X, Huang K, Ma P, Jiang P Oncol Lett. 2019; 18(3):2789-2798.

PMID: 31452757 PMC: 6676647. DOI: 10.3892/ol.2019.10607.

References

Chiang J, Chou Y, Ma S, Chen J . Influence of age on adenomatous polyposis coli and p53 mutation frequency in sporadic colorectal cancer-rarity of co-occurrence of mutations in APC, K-ras, and p53 genes. Virchows Arch. 2004; 445(5):465-71. DOI: 10.1007/s00428-004-1116-z. View

Liang J, Chang K, Chen J, Lee C, Cheng Y, Hsu H . Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival. Oncology. 1999; 57(2):149-56. DOI: 10.1159/000012023. View

Kim B, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan C . Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol. 2005; 26(5):1217-26. View

Giehl K . Oncogenic Ras in tumour progression and metastasis. Biol Chem. 2005; 386(3):193-205. DOI: 10.1515/BC.2005.025. View

Pizzi S, Azzoni C, Bottarelli L, Campanini N, DAdda T, Pasquali C . RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol. 2005; 206(4):409-16. DOI: 10.1002/path.1784. View

Jeong J, Park Y, Park J, Yoon D, Chi H, Kim B . Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med J. 2005; 46(4):519-25. PMC: 2815837. DOI: 10.3349/ymj.2005.46.4.519. View

Kim H, Roh S, Ga I, Kim J, Yu C, Kim J . CpG island methylation as an early event during adenoma progression in carcinogenesis of sporadic colorectal cancer. J Gastroenterol Hepatol. 2005; 20(12):1920-6. DOI: 10.1111/j.1440-1746.2005.03943.x. View

Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G . A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006; 93(4):465-74. DOI: 10.1002/bjs.5278. View

Toyota M, Issa J . CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol. 1999; 9(5):349-57. DOI: 10.1006/scbi.1999.0135. View

10.

Toyota M, Ahuja N, Issa J . Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proc Natl Acad Sci U S A. 2000; 97(2):710-5. PMC: 15395. DOI: 10.1073/pnas.97.2.710. View

11.

Kolch W . Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000; 351 Pt 2:289-305. PMC: 1221363. View

12.

Wheeler J, Kim H, Efstathiou J, Ilyas M, Mortensen N, Bodmer W . Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer. Gut. 2001; 48(3):367-71. PMC: 1760130. DOI: 10.1136/gut.48.3.367. View

13.

Yi J, Wang Z, Cang H, Chen Y, Zhao R, Yu B . p16 gene methylation in colorectal cancers associated with Duke's staging. World J Gastroenterol. 2002; 7(5):722-5. PMC: 4695583. DOI: 10.3748/wjg.v7.i5.722. View

14.

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

15.

Smith G, Carey F, Beattie J, Wilkie M, Lightfoot T, Coxhead J . Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2002; 99(14):9433-8. PMC: 123158. DOI: 10.1073/pnas.122612899. View

16.

Roncalli M, Bianchi P, Bruni B, Laghi L, Destro A, Di Gioia S . Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma. Hepatology. 2002; 36(2):427-32. DOI: 10.1053/jhep.2002.34852. View

17.

Bazan V, Migliavacca M, Zanna I, Tubiolo C, Grassi N, Latteri M . Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol. 2002; 13(9):1438-46. DOI: 10.1093/annonc/mdf226. View

18.

Rajagopalan H, Bardelli A, Lengauer C, Kinzler K, Vogelstein B, Velculescu V . Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418(6901):934. DOI: 10.1038/418934a. View

19.

Garinis G, Menounos P, Spanakis N, Papadopoulos K, Karavitis G, Parassi I . Hypermethylation-associated transcriptional silencing of E-cadherin in primary sporadic colorectal carcinomas. J Pathol. 2002; 198(4):442-9. DOI: 10.1002/path.1237. View

20.

Yuen S, Davies H, Chan T, Ho J, Bignell G, Cox C . Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002; 62(22):6451-5. View